Melphalan flufenamide (melflufen)
Pepaxto · Peptide-conjugated alkylator
Delivers melphalan intracellularly; BRIDGE supports a reduced 30 mg dose in moderate renal impairment.
Aqupla · NDP
Platinum agent · approved 1995 · 11 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A second-generation platinum engineered to spare the kidney that cisplatin punishes.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Lower renal cortical platinum accumulation and less frequent nephrotoxicity than equimolar cisplatin; dose-related proximal tubular injury still occurs, but high-grade AKI is uncommon and not robustly quantified in the renal literature. Myelosuppression (notably thrombocytopenia), not nephrotoxicity, is the dose-limiting toxicity. Reported rate: serum creatinine elevation in 9.8% — Patients with gastrointestinal cancer (esophageal, stomach, colon) in a 16-institution Japanese phase II study of… (Taguchi 1992, PMID 1558398).Source: Taguchi et al., Gan To Kagaku Ryoho 1992
AKI days after dosing, accumulating with repeated cycles.
Distilled from: “Days after dosing; cumulative with repeated cycles.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Tap a signature to trace where it strikes the nephron.
Representative incidence
Acute Tubular Necrosis strikes: Proximal Tubule, Distal Tubule / Collecting Duct.
Acute Tubular Necrosis
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Cytotoxic platinum(II) compound (cis-diammine-glycolato-platinum) that, after aquation, forms intrastrand 1,2-d(GpG) DNA cross-links, blocking replication and transcription and triggering apoptosis. Its glycolate leaving group gives more favorable aqueous handling and lower tissue retention than cisplatin. Used mainly in Japan for head and neck, esophageal, lung, cervical, ovarian, and germ cell cancers.
Class-level context for the major non-renal toxicities of the Platinum agent class.
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
Hematologic
Cytopenias, thrombosis, TMA
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
9 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Everything below is FAERS — adverse events someone chose to report, about 1,100 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
128 of 1,100 reports
Reported with hospitalization
428 of 1,100 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 28 of the 1,100 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Nedaplatin sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Pepaxto · Peptide-conjugated alkylator
Delivers melphalan intracellularly; BRIDGE supports a reduced 30 mg dose in moderate renal impairment.
Emrelis · c-Met ADC (MMAE)
c-Met MMAE antibody-drug conjugate; proximal tubular ATN risk extrapolated from the ADC/MMAE class.
Mithracin · Antitumor antibiotic
Cumulative tubular ATN; hypocalcemia is an on-target antiresorptive effect.
Yondelis · Marine alkylating agent
Rhabdomyolysis → pigment nephropathy; hepatotoxicity.
Padcev · Antibody-drug conjugate (Nectin-4/MMAE)
Emerging AKI and electrolyte signals in urothelial cancer.
Enhertu · Antibody-drug conjugate (HER2/DXd)
Emerging AKI/proteinuria reports — under-published.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Nedaplatin’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Nedaplatin; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 36 clinical records among all 77 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.